Lundbeck Inc. has acquired Dutch biopharma company Prexton Therapeutics for €100m upfront, with milestone payment agreements expected to reach €805m, for the smaller firm's Phase II Parkinson's drug foliglurax.
Through Prexton, Lundbeck will obtain global rights to foliglurax, which currently is in clinical Phase II testing for symptomatic treatment...








